Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PLRZ

Polyrizon Ltd

Feb 06 • 04:00PM ET

12.85

+0.41 3.34 %

Healthcare • Biotechnology • Israel • NASD

Feb 06, 8:00 AMPolyrizon announces a development agreement with Clearmind Medicine to create a proprietary intranasal formulation of Clearmind’s non‑hallucinogenic neuroplastogen drug candidate MEAI for CNS and addiction-related indications.

Peers: REVB THAR PALI PMCB SLXN NERV BCDA HYFT BBLG SNSE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-342.98	Insider Own	19.98%	Shs Outstand	1.59M	Perf Week	11.60%
Market Cap	20.47M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.28M	Perf Month	3.80%
Enterprise Value	4.64M	PEG	-	EPS next Q	-	Inst Own	0.06%	Short Float	9.38%	Perf Quarter	121.27%
Income	-1.13M	P/S	-	EPS this Y	-	Inst Trans	-64.07%	Short Ratio	0.04	Perf Half Y	84.55%
Sales	0.00M	P/B	0.69	EPS next Y	-	ROA	-11.74%	Short Interest	0.12M	Perf YTD	51.30%
Book/sh	18.75	P/C	1.29	EPS next 5Y	-	ROE	-12.20%	52W High	2235.00 -99.43%	Perf Year	-99.27%
Cash/sh	9.93	P/FCF	-	EPS past 3/5Y	-29.52% -	ROIC	-6.17%	52W Low	2.88 346.01%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	20.21% 14.19%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	3.81%	Oper. Margin	-	ATR (14)	2.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	44.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.80	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	44.04	EPS Q/Q	99.65%	SMA20	-10.50%	Beta	-5.85	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	12.16%	Rel Volume	0.02	Prev Close	12.43
Employees	6	LT Debt/Eq	0.00	Earnings	-	SMA200	-78.72%	Avg Volume	3.16M	Price	12.85
IPO	Oct 29, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	67,397	Change	3.34%

Feb-06-26 07:55AM	Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation (GlobeNewswire)
Feb-04-26 07:12AM	Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company (GlobeNewswire) -15.16%
Jan-22-26 09:25AM	Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX Allergy Blocker (GlobeNewswire)
Jan-13-26 08:39AM	Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet (GlobeNewswire)
Jan-08-26 08:45AM	Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX (GlobeNewswire) +8.36%
09:07AM	Loading…
Jan-05-26 09:07AM	Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator (GlobeNewswire)
Jan-02-26 08:30AM	As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated (GlobeNewswire) +50.18%
Dec-29-25 07:20AM	Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet (GlobeNewswire)
Dec-19-25 08:20AM	Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses (GlobeNewswire) -6.73%
Dec-11-25 08:15AM	Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program (GlobeNewswire) +11.46%
Dec-08-25 08:55AM	Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray (GlobeNewswire) -15.65%
Dec-05-25 10:26AM	This Former Penny Stock Just Doubled for the Second Time This Week. Should You Chase the Rally Here? (Barchart) -9.66%
Dec-04-25 07:32AM	From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection (GlobeNewswire) +104.51%
Dec-03-25 09:28AM	Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product (GlobeNewswire)
Dec-02-25 07:55AM	Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform (GlobeNewswire) +131.96%
08:55AM	Loading…
Nov-06-25 08:55AM	Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation (GlobeNewswire) -5.31%
Oct-06-25 08:21AM	Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy (GlobeNewswire)
Sep-19-25 08:15AM	Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker (GlobeNewswire) +7.69%
Sep-12-25 07:26AM	Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study (GlobeNewswire) +22.76%
Aug-14-25 08:14AM	Polyrizon Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.89%
Jul-23-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +29.66%
Jul-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +59.73%
08:32AM	Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study (GlobeNewswire)
Jul-15-25 07:55AM	Polyrizon Retains Nasdaq Listing Following Hearings Panel (GlobeNewswire) +52.47%
Jun-12-25 07:32AM	Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics (GlobeNewswire) +33.75%
May-23-25 04:15PM	Polyrizon Announces Receipt of Nasdaq Delisting Notice (GlobeNewswire) -19.05% -24.00%
May-21-25 07:10AM	Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform (GlobeNewswire)
May-13-25 07:45AM	Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment (GlobeNewswire) -91.86%
May-03-25 11:00AM	Ford, Disney, And AMD To Report Results Next Week (Seeking Alpha)
Apr-25-25 07:37AM	Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model (GlobeNewswire)
04:15PM	Loading…
Apr-11-25 04:15PM	Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements (GlobeNewswire) +6.04%
Apr-02-25 09:05AM	Polyrizon Engages Leading Branding Firm for Strategic Brand Development (GlobeNewswire) +7.52%
Apr-01-25 04:09PM	Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement (GlobeNewswire)
Mar-31-25 09:32AM	Polyrizon Ltd. Announces $17.0 Million Private Placement (GlobeNewswire) -22.93%
Mar-27-25 08:25AM	Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting (GlobeNewswire) +6.09%
Mar-25-25 04:04PM	Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment (GlobeNewswire) -27.95% -12.96%
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks)
Mar-19-25 07:35AM	Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination (GlobeNewswire)
Mar-14-25 08:35AM	Polyrizon Signs Non Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments (GlobeNewswire) -17.65%
Mar-13-25 07:51AM	Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform (GlobeNewswire)
Mar-11-25 04:27PM	Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 (GlobeNewswire) -6.25% -6.27%
Mar-10-25 07:47AM	Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform (GlobeNewswire)
Jan-30-25 05:55AM	Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target (T&T) Intranasal Drug Delivery Platform (GlobeNewswire)
Jan-23-25 06:40AM	Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial (GlobeNewswire) -5.41%
Dec-30-24 06:25AM	Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies (GlobeNewswire) +31.71%
Dec-19-24 07:22AM	Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs (GlobeNewswire) -29.18%
Dec-18-24 06:25AM	Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker (GlobeNewswire) +213.33%
Dec-13-24 06:25AM	Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance (GlobeNewswire)
Dec-02-24 08:02AM	Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial (GlobeNewswire) +30.13%
Oct-30-24 01:50PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ) (ACCESSWIRE) +8.39%
10:28AM	Polyrizon Announces Closing of $4.2 Million Initial Public Offering (GlobeNewswire)

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLRZ

Polyrizon Ltd

Upgrade your FINVIZ experience